Company: LNAI
Filing Date: 2025-10-15
Form Type: DEF 14A
Source: 0001731122-25-001378
Chunk: 44

Company: Lunai Bioworks Inc.
Filing Date: 2025-10-15
Form: DEF 14A
Chunk 44
---
 the 2023 Incentive Plan |     | $                     |      4.54 |
| Weighted-average remaining term of outstanding Stock Options under the 2023 Incentive Plan |     |                       |      8.43 |
| Total number of shares available for grant under the 2023 Incentive Plan (1)               |     |                       |   434,067 |
| Additional shares requested under this Incentive Plan Proposal                             |     |                       | 3,042,655 |

(1) On February 6, 2014, the Company’s Board of Directors adopted the Company’s 2014 Equity Incentive Plan (the “ 2014 Plan”), and the Company had reserved 120,600 shares of Common Stock for issuance in accordance with the terms of the 2014 Plan.

On October 30,
2019, the Board approved and on October 31, 2019, the Company’s stockholders adopted its 2019 Equity Incentive Plan (the “”), which replaced the 2014 Plan. The 2019 Plan provided that the maximum aggregate number of shares of the Company’s
Common Stock reserved and available for issuance under the 2019 Plan was the sum of (1) 600,000 new shares, and (2) the number of shares
available for the grant of awards as of the effective date under the 2014 Plan plus any options related to awards that expire, are terminated,
surrendered, or forfeited for any reason without issuance of shares under the 2014 Plan after the effective date of the 2019 Plan.

Effective July 21, 2023, the Company
adopted the Renovaro Biosciences Inc. 2023 Equity Incentive Plan (the “”). The 2023 Plan replaced the 2019
Plan. The 2023 Plan provides that the maximum aggregate number of shares of the Company’s Common Stock reserved and available for
issuance under the 2023 Plan was the sum of (1) 400,000 new shares, and (2) the number of shares available for the grant of awards as
of the effective date under the 2019 Plan. Any awards outstanding under the 2019 Plan as of the date of adoption of the 2023 Plan remain
subject to and will be available under the 2019 Plan, and any shares subject to outstanding awards under the 2019 Plan that subsequently
expire, terminate,